Interpace Biosciences Inc
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis of pancreaticobiliary cancers using its proprietary PathFinderTG platform; PanDNA, a molecular only version of PancraGEN; and ThyGeNEXT, an … Read more
Market Cap & Net Worth: Interpace Biosciences Inc (IDXG)
Interpace Biosciences Inc (OTCQX:IDXG) has a market capitalization of $24.93 Million ($24.93 Million) as of March 18, 2026. Listed on the OTCQX stock exchange, this USA-based company holds position #34482 globally and #11245 in its home market, demonstrating a -21.74% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Interpace Biosciences Inc's stock price $0.90 by its total outstanding shares 27695866 (27.70 Million).
Interpace Biosciences Inc Market Cap History: 2015 to 2025
Interpace Biosciences Inc's market capitalization history from 2015 to 2025. Data shows change from $1.29 Billion to $24.93 Million (-42.19% CAGR).
Interpace Biosciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Interpace Biosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.83x
Interpace Biosciences Inc's market cap is 1.83 times its annual revenue
0.69x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
12.81x
Interpace Biosciences Inc's market cap is 12.81 times its annual earnings
363.13x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.29 Billion | $9.43 Million | -$11.36 Million | 136.54x | N/A |
| 2016 | $1.22 Billion | $13.09 Million | -$8.33 Million | 93.13x | N/A |
| 2017 | $282.50 Million | $15.90 Million | -$12.22 Million | 17.77x | N/A |
| 2018 | $221.57 Million | $21.90 Million | -$12.19 Million | 10.12x | N/A |
| 2019 | $138.48 Million | $24.22 Million | -$26.74 Million | 5.72x | N/A |
| 2020 | $86.97 Million | $32.40 Million | -$26.45 Million | 2.68x | N/A |
| 2021 | $206.89 Million | $41.31 Million | -$14.94 Million | 5.01x | N/A |
| 2022 | $28.80 Million | $31.84 Million | -$21.96 Million | 0.90x | N/A |
| 2023 | $29.91 Million | $40.04 Million | $1.95 Million | 0.75x | 15.31x |
| 2024 | $85.86 Million | $46.93 Million | $6.70 Million | 1.83x | 12.81x |
Competitor Companies of IDXG by Market Capitalization
Companies near Interpace Biosciences Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Interpace Biosciences Inc by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #90 globally with a market cap of $177.20 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #151 globally with a market cap of $122.79 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #466 globally with a market cap of $46.38 Billion USD.
- Lonza Group Ltd (PINK:LZAGF): Ranked #511 globally with a market cap of $41.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #90 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.20 Billion | $472.71 |
| #151 | Danaher Corporation | NYSE:DHR | $122.79 Billion | $195.21 |
| #466 | IDEXX Laboratories Inc | NASDAQ:IDXX | $46.38 Billion | $586.98 |
| #511 | Lonza Group Ltd | PINK:LZAGF | $41.73 Billion | $596.13 |
Interpace Biosciences Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Interpace Biosciences Inc's market cap moved from $1.29 Billion to $ 24.93 Million, with a yearly change of -42.19%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $24.93 Million | -70.97% |
| 2024 | $85.86 Million | +187.04% |
| 2023 | $29.91 Million | +3.85% |
| 2022 | $28.80 Million | -86.08% |
| 2021 | $206.89 Million | +137.90% |
| 2020 | $86.97 Million | -37.20% |
| 2019 | $138.48 Million | -37.50% |
| 2018 | $221.57 Million | -21.57% |
| 2017 | $282.50 Million | -76.82% |
| 2016 | $1.22 Billion | -5.38% |
| 2015 | $1.29 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Interpace Biosciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $24.93 Million USD |
| MoneyControl | $24.93 Million USD |
| MarketWatch | $24.93 Million USD |
| marketcap.company | $24.93 Million USD |
| Reuters | $24.93 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.